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Tuberculosis and cardiovascular disease:
linking the epidemics
Moises A. Huaman1*†, David Henson1†, Eduardo Ticona2, Timothy R. Sterling3 and Beth A. Garvy1,4
Abstract
The burden of tuberculosis and cardiovascular disease (CVD) is enormous worldwide. CVD rates are rapidly
increasing in low- and middle-income countries. Public health programs have been challenged with the
overlapping tuberculosis and CVD epidemics. Monocyte/macrophages, lymphocytes and cytokines involved in
cellular mediated immune responses against Mycobacterium tuberculosis are also main drivers of atherogenesis,
suggesting a potential pathogenic role of tuberculosis in CVD via mechanisms that have been described for other
pathogens that establish chronic infection and latency. Studies have shown a pro-atherogenic effect of antibody-
mediated responses against mycobacterial heat shock protein-65 through cross reaction with self-antigens in
human vessels. Furthermore, subsets of mycobacteria actively replicate during latent tuberculosis infection (LTBI),
and recent studies suggest that LTBI is associated with persistent chronic inflammation that may lead to CVD.
Recent epidemiologic work has shown that the risk of CVD in persons who develop tuberculosis is higher than in
persons without a history of tuberculosis, even several years after recovery from tuberculosis. Together, these data
suggest that tuberculosis may play a role in the pathogenesis of CVD. Further research to investigate a potential
link between tuberculosis and CVD is warranted.
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Background
Non-communicable diseases caused 38 of the 56 million
deaths reported globally in 2012. About half of these
deaths were related to cardiovascular disease (CVD) [1].
CVD is expected to be the major cause of death for most
developing countries by 2020, similar to the current epi-
demiology of CVD in developed nations [2, 3]. Com-
pared to high-income countries, CVD occurs at a
younger age and causes a larger proportion of premature
deaths in low- and middle-income countries [4]. Trad-
itional risk factors such as obesity, hypertension and dia-
betes explain much of this increase [4], but studies
indicate that the burden of infection may also contribute
to the development of CVD [5].
Over 2 billion persons are infected with Mycobacter-
ium tuberculosis globally and about 2 million die from
tuberculosis disease every year [6]. Tuberculosis and
non-communicable diseases may not only co-exist, but
also augment the risk of each other [7]. This review
seeks to explore the association between tuberculosis
and CVD.
Review
A connection between infection and cardiovascular
disease
The hypothesis that infection has a pathogenic role in
CVD was first suggested by clinical observations. The
first convincing evidence of a connection between infec-
tion and CVD arose from the work by Fabricant et al.
more than 3 decades ago [8]. This group showed that in-
fection of chickens with Marek’s disease virus, an avian
herpesvirus, caused atherosclerotic lesions in coronary
arteries and other vessels [9]. In 1992, Shor et al. in
South Africa found Chlamydia pneumoniae in the fatty
streaks of coronary artery plaques [10]. Subsequent ex-
periments in animal models supported a pathogenic role
of C. pneumoniae in atheroma formation [11–13].
Serologic studies followed and showed an association
between C. pneumoniae antibodies and CVD in
humans [14]. Similarly, Helicobacter pylori exists in
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atherosclerotic plaques, and elimination of the infec-
tion increases the coronary artery lumen and reduces
cardiac event rates [15, 16]. Influenza virus is associ-
ated with acute myocardial infarction (AMI) [17], as
well as accelerated development of early coronary ar-
tery plaques [18, 19]. Human immunodeficiency virus
(HIV) has also been linked to CVD. HIV infection in-
creases the risk of cardiovascular events 1.5 – 2-fold
after adjusting for traditional CVD risk factors [20].
This appears to be mediated at least in part by
chronic immune activation caused by HIV, even after
suppressing the virus with antiretroviral therapy [21].
Infections due to hepatitis B virus [22], hepatitis C
[23], Epstein Barr virus [24, 25], cytomegalovirus
(CMV) [26, 27] and periodontal bacteria [28] have
also been associated with atherosclerosis and CVD
through chronic systemic inflammation and other
mechanisms. Notably, most of the pathogens impli-
cated in CVD pathogenesis are intracellular organisms
and/or may be able to establish chronic or latent in-
fection in humans [29]. This may cause persistent
local or systemic inflammation that can lead to ath-
erosclerotic plaque formation. Recent studies suggest
that latent tuberculosis infection (LTBI) is associated
with chronic inflammation therefore a connection be-
tween LTBI and CVD seems plausible [30, 31].
The effect of acute infection on short-term cardiovas-
cular events has also been studied. Acute lower respira-
tory tract infections carry a high risk of subsequent AMI
or stroke. A large population-based retrospective study
conducted in the United Kingdom showed a 5-fold in-
crease of AMI in patients diagnosed with an acute sys-
temic respiratory infection within the prior 3 days.
Furthermore, the risk of AMI remained elevated 1 to
3 months after the infection [32]. M. tuberculosis pri-
marily causes pulmonary disease. Although sub-acute or
chronic presentation is common, acute illness from tu-
berculosis can also occur [33]. A recent report showed
that persons with pulmonary or extrapulmonary tuber-
culosis had an increased subsequent risk of AMI and
unstable angina. Surprisingly, the risk remained elevated
after several years from the initial diagnosis of tuber-
culosis suggesting that tuberculosis disease may have
short-term and long-term implications in CVD [34].
Alternatively, developing tuberculosis disease may just
be a marker of background dysfunctional immune re-
sponses in susceptible hosts, as these same abnormal
responses that predispose to tuberculosis may also
predispose to CVD.
Mechanisms of the effect of infection on cardiovascular
disease
Two main themes dominate the proposed mechanism
that connects infection and CVD; 1) an increase in
inflammation leading to coronary artery plaque forma-
tion and/or plaque rupture, and 2) autoimmune disease.
An additional hypothesis is that pathogens inhabit grow-
ing atherosclerotic plaques, and cause direct vascular
damage [5].
For an infectious disease to cause CVD via an increase
in inflammation it stands to reason that the infection
must trigger host immunologic responses similar to
those implicated in atherogenesis. Plaques begin as a
small inflammatory process seen as reversible fatty
streaks in the innermost part of the artery [35]. Endothe-
lial cells are activated by released phospholipids and
other stimuli, and this activation increases surface adhe-
sion molecules (i.e.; intracellular adhesion molecule-1,
ICAM-1) that bind immune cells including circulating
monocytes, lymphocytes and others [36]. These immune
cells access the intima and accelerate plaque growth
[37]. CD4+ cells of the T helper 1 (TH1) type play a key
role in atherogenesis. The production of interferon
(IFN)-γ, tumor necrosis factor (TNF)-α and interleukin
(IL)-1 by these CD4+ TH1 cells contribute to growth of
the plaque, as does macrophage colony stimulating factor
produced by endothelial cells [38, 39]. These chemokines
activate monocyte/macrophages and other immune cells
in a positive feedback loop [39]. Studies have shown the
important role of IFN-γ, particularly in atherogenesis [40].
Mice without IFN-γ signaling develop plaque at a substan-
tially lower rate compared to mice with IFN-γ signaling
[41]. As these plaques progress through stages of develop-
ment they become covered by a cap of smooth-muscle
cells and collagen-rich matrix. Some plaques may include
calcifications and thrombi [35]. The most vulnerable part
of the plaque, the cap, may rupture when triggered by a
variety of stresses. Plaque rupture causes 60 % to 70 % of
coronary artery thrombotic events [42].
Inflammation related to infection can augment many
of these steps, from early plaque formation to ultimate
plaque rupture. Furthermore, pathogens may not need
to be fully proliferating to cause inflammation [5]. For
instance, a study of the mechanism of Epstein Barr virus
(EBV) in CVD showed that the presence of neutralizing
antibodies to an early EBV protein was associated with
higher levels of IL-6 and ICAM-1 in patients with AMI
compared to patients with stable angina [25]. This pro-
tein, deoxyuridine triphosphate nucleotidohyrolase, is an
early EBV product expressed during lytic and abortive-
lytic EBV replication that leads to NF-κβ activation
through toll like receptor 2 [43]. Thus even under condi-
tions of incomplete viral replication EBV may have a
role in precipitating AMI [25]. Similarly, studies indicate
that non-replicating CMV may stimulate the host im-
mune system and promote atherogenesis [44].
The most common cross reaction of antibodies from
infection to self-proteins in atherosclerosis centers on
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the heat shock protein (HSP) system [45]. The HSP sys-
tem has been strongly conserved throughout evolution.
The sequence of human HSP60 has 40–50 % identical
residues, and 20 % conservative replacements to HSP65
in Mycobacterium spp. and HSP60 in Escherichia coli
[46]. This conservation of epitopes results in a cross-
reaction between antibodies produced to bacterial HSP
such as E. coli HSP60, chlamydial HSP60 or mycobacter-
ial HSP65, and the self HSP60 in humans. Perschinka
et al. showed that antibodies against bacterial HSP60/65
also bound the homologues epitopes on human HSP60
[47]. A study showed that antibodies to HSP65 were the
only antibodies significantly tied to CVD [48]. This is
critically important because endothelial cells express
HSP on their surface when they are activated by infec-
tion or other stressors [48]. This expression provides a
target for the immune reaction to HSP, which can lead
to plaque development. A heightened level of anti-
HSP65 antibody was found in individuals with elevated
coronary calcification scores, after controlling for other
cardiac risk factors [49].
Evidence connecting tuberculosis disease and
cardiovascular disease
The hypothesis that tuberculosis leads to CVD comes
from case studies of tuberculosis causing cardiovascular
death as well as from population based studies that show
increased risk of cardiovascular events.
Tuberculous granuloma formation affecting the coron-
ary arteries has been described as a rare cause of myo-
cardial infarction in young patients [50, 51]. The idea
that infection could predispose to CVD early in life is
supported by work by Dummer et al. who found a cor-
relation between CMV infection and coronary athero-
sclerosis of explanted hearts in young patients who
underwent heart transplantation, but not among older
individuals [52]. It is possible that tuberculosis could be
contributing to premature cardiovascular death in areas
of high tuberculosis prevalence.
M. tuberculosis may not only affect the coronary ves-
sels, but also the myocardium. Liu et al. summarized
available clinical cases of tuberculous myocarditis and
related sudden cardiac death (SCD) [53]. Most patients
were young and asymptomatic prior to their fatal event.
The proposed underlying mechanism leading to SCD
was ventricular tachyarrhythmia, likely a consequence of
aberrant conduction from extensive tuberculous septal
involvement or ventricular wall necrosis [54, 55]. Pul-
monary tuberculosis without obvious direct mycobacter-
ial involvement of the myocardium or coronary arteries
has also been liked to SCD, but the exact mechanisms of
death remain obscure [56].
A large population-based retrospective cohort study
conducted in Taiwan goes beyond these individual
clinical observations to look at baseline CVD risk eleva-
tion in patients who had tuberculosis disease. The re-
searchers looked at 10,168 patients with a history of
tuberculosis disease and 40,672 control patients without
a history of tuberculosis disease. After adjusting for im-
portant co-morbidities, the tuberculosis group had a 40 %
increased risk of the composite endpoint of unstable an-
gina and AMI compared to the non-tuberculosis group.
This elevated risk persisted for the entire study period of
up to 14 years [34].
The potential effects of tuberculosis disease do not ap-
pear to be limited to coronary heart disease (CHD) but
extend to other atherosclerosis-mediated vascular dis-
eases such as stroke. A study in Taiwan followed patients
with a history non-meningeal tuberculosis disease and
no history of stroke, as well as control patients. The au-
thors found a 50 % increased risk of ischemic stroke in
the tuberculosis group after 3 years of follow-up. This
study also showed an increased risk of CHD in the tu-
berculosis group [57].
Mechanism of cardiovascular disease in tuberculosis
disease
The possible mechanisms of CVD in tuberculosis are
summarized in the Table 1. In tuberculous myocarditis
or coronary arteritis the relationship between infection
and CVD is direct and apparent. However, these extra-
pulmonary complications of M. tuberculosis disease
seem rare [53]. As in other infections, the role of chronic
inflammation and HSP-based autoimmunity may have
consequences in CVD at a much larger scale.
In tuberculosis, the innate immune system initiates an
immune response within the lung. This response deploys
large numbers of phagocytic cells, which also play host
to Mycobacterium tuberculosis [58, 59]. As the reaction
progresses, immune cells continue to accumulate in the
lungs so that more host cells become available to the
bacteria, and eventually a granuloma forms. Granuloma
formation relies on inflammatory chemical mediators to
bring other immune cells to the site of infection [60].
After the initial innate immune reaction, immunological
equilibrium develops via an adaptive response. Once the
Table 1 Possible mechanisms of cardiovascular disease in
tuberculosis
Direct effect on the myocardium (tuberculous myocarditis)
Direct effect on coronary arteries (tuberculous arteritis)
Increased expression of pro-inflammatory citokines (i.e., IL-1, IL-2, IL-6,
IFN-γ, TNF-α)
Monocyte/macrophage immune activation
CD4+ TH1 and TH17 cell immune activation
Auto-immunity mediated by antibodies against mycobacterial HSP65
Abreviations: HSP65 heat shock protein 65, IL interleukin, IFN interferon, TH1 T
helper 1, TH17, T helper 17, TNF tumor necrosis factor
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adaptive response is established, CD4+ T cells become
activated and release a plethora of cytokines to modulate
the immune response against M. tuberculosis [61]. Simi-
lar to inflammatory responses related to CVD, TNF-α
and IFN-γ are of particular importance. Blockage of ei-
ther leads to severe mycobacterial infections [62–64].
Patients with tuberculosis disease also have a significant
elevation in IL-1, IL-2, IL-6 and IL-22. The total level of
T cells is decreased, but those present shift strongly to a
TH1 type. When stimulated with mycobacterial anti-
gens, they readily produce IL-17, IL-22 and IFN-γ [30].
This TH1 inflammation matches the inflammatory pro-
file of plaque formation presented earlier. Thus, tubercu-
losis may have a pathogenic role in CVD through
activation of cell-mediated immune responses that pro-
mote atherogenesis.
Emerging evidence indicates a role for IL-17 and the
CD4+ subset T helper 17 (TH17) cells in immune re-
sponses to tuberculosis [65]. Early in the immune re-
sponse to tuberculosis IL-17 production is dominated by
γδ cells [66]. IL-17 is required for the development of a
mature granuloma possibly through an increase in cell
adhesion molecules [67]. In long term immune response
the production of IL-17 is maintained by antigen specific
TH17 cells, and without this response antimicrobial ac-
tivity in the lungs is reduced [68]. IL-17 deficient mice
show an impaired response to virulent tuberculosis [67].
In atherosclerosis, TH17 cells have been regarded both
protective and pathogenic roles [69]. Pathogenic TH17
cells are induced by IL-6, IL-23 and IL-1β; and produce
IL-17 and IFN- γ [70, 71]. Pathogenic TH17 cells have
been found in atherosclerotic plaques of mice and
humans, and the presence of both IL-17 and IFN- γ have
a synergistic pro-inflammatory effect on vascular smooth
muscle cells [72]. It is possible that TH17 cells impli-
cated in immune responses to tuberculosis may have a
role in atherogenesis.
Studies show that mycobacterial HSP65 share hom-
ology to human HSP60 [46]. Antibodies specific to the
entire mycobacterial HSP65 cross-react with human
HSP60. When antibodies are targeted to specific epi-
topes of mycobacterial HSP65, cross reactivity remains
[47]. Injection of mycobacterial HSP65 protein induces
arteriosclerosis in rabbits with both normal and elevated
cholesterol levels, unlike any other control antigen [73].
In humans, a significant correlation between anti-HSP65
antibodies and carotid atherosclerosis has been reported
[48, 49]. These data suggest that tuberculosis could have
a pathogenic role in CVD through molecular mimicry
and auto-immunity mediated by anti-HSP65 antibodies.
Tuberculosis and Takayasu’s arteritis
A connection between tuberculosis and Takayasu’s arter-
itis (TA) has been suggested. TA is a chronic vasculitis
of unknown origin that primarily affects the aorta and
its main branches. The diagnosis and treatment of TA
was recently reviewed by Isobek [74].
In 1981 Pantell et al. presented a compilation of case
series from Japan, Korea, India, Mexico and South Africa
that included 747 cases of TA. The rates of tuberculosis
disease in these case series ranged from 22 % to 70 %,
compared to tuberculosis rates of 0.03 % to 1.5 % for the
general population in those countries [75]. This report
and others that followed suggested an association be-
tween tuberculosis disease and TA [76]; however, further
investigation is clearly needed. Aggarwal et al. looked at
antibody titers against M. tuberculosis proteins including
HSP65 in TA. The authors found a significant increase
in immunoglobulin (Ig) G, IgM, and IgA titers to M. tu-
berculosis antigens; and IgM and IgA titers against
HSP65 in patients with TA compared to control patients
without TA. Although this would further support a po-
tential link between tuberculosis and TA, the authors
postulated that the observed antibody responses could
also be secondary to prior Bacillus Calmette-Guerin
(BCG) vaccination [77].
Latent tuberculosis infection and cardiovascular disease
A link between LTBI and CVD via chronic inflammation
seems biologically plausible. The classic model of LTBI
stipulates that mycobacteria in the inflammatory capsule
do not divide but remain in stasis, enduring the environ-
ment unsuitable for growth. The constant level of colony
forming units isolated from LTBI lesions indicated this
lack of division. Researchers supported this model by
testing the count of M. tuberculosis within the tubercles
by using rtPCR and showed that the level of genetic ma-
terial within a tubercle does not change overtime [78].
The first indication that this picture might be incom-
plete came from the clinical experience with isoniazid.
This antibiotic is active against LTBI but only shows ef-
fectiveness against dividing mycobacterium both in vitro
and in vivo [79, 80]. Therefore if isoniazid works in LTBI
then mycobacterial division would be expected to occur
in the latent form. Gill et al. demonstrated that there is
continued replication of mycobacterium in chronically
infected mice. This group inserted an unstable plasmid
into M. tuberculosis and showed that tissue levels of the
plasmid decreased with every division of the bacterium.
Because the total number of bacteria remained constant
the authors concluded that bacteria that die must be
cleared away from the site by the host immune system
therefore giving a false impression of absent replication
[81]. These data suggests that subsets of mycobacteria
are actively dividing in LTBI, and a dynamic equilibrium
between the host immune system and the bacteria is
established during latency. In this context, a degree of
chronic inflammation driven by LTBI is possible.
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Furthermore, studies in cynomolgus macaques infected
with latent tuberculosis have shown that each granuloma
within a single host possesses a unique profile of T cells
and pro- and anti-inflammatory cytokines leading to a
spectrum of granulomas with differential mycobacterial
killing capacity within the same host at any given time,
demonstrating that immune responses and bacterial bur-
den in LTBI are quite dynamic [82].
A study of immune activation in patients with latent
and active tuberculosis in Canada showed an inflamma-
tory profile consistent with this model. The baseline cir-
culating levels of TNF-α, IL-1β, IL-4, IL-8, and IL-22
were all significantly elevated in patients with LTBI com-
pared to healthy controls with a negative tuberculin skin
test (TST). IFN-γ levels were also higher in the LTBI
group compared to healthy controls but the difference
was not statistically significant [30]. Similarly, a study of
HIV-infected persons in South Africa showed elevated
levels of circulating soluble CD14, C-reactive protein,
IL-6 and interferon gamma-induced protein 10 (IP10)
among patients with HIV and LTBI co-infection, com-
pared to HIV patients without evidence of tuberculosis
infection based on a negative TST, negative IFN- γ
ELISpot, negative chest-X-ray, negative induced spu-
tum for M. tuberculosis and no tuberculosis disease
symptoms [31].
A recent study looked at markers of systemic inflam-
mation in persons with tuberculosis disease, LTBI, prior
tuberculosis, and healthy controls in India. Compared to
healthy controls, patients with LTBI were found to have
higher levels of monocyte/macrophage activation and in-
flammatory mediators including CD14, CXCL3, CCL2
and CCL8. This suggests a switch from neutrophil to
monocyte/macrophage centered responses in these pa-
tients. The authors concluded that LTBI may induce
long-term persistent inflammation, even in the absence
of tuberculosis disease [83]. Interestingly, these re-
searchers also found similar monocyte/macrophage acti-
vation markers in persons cured from prior tuberculosis,
which may explain the increased risk for AMI and un-
stable angina observed years after recovery from tuber-
culosis in the Taiwan cohort study discussed above [34].
Not all studies that looked at LTBI and inflammatory
markers found a positive association. For instance, de-
creased IL-17 expression and increased T regulatory cell
activity has been described in the context of LTBI [84].
Wergeland et al. showed that CD4+ T cell activation in
LTBI is lower than in tuberculosis disease. However, a
wide range of CD4+ T cell activation was present in per-
sons with LTBI [85]. The authors postulate that this
could be an indication of differential immune activation
throughout the stages of tuberculosis infection and re-
lated mycobacterial burden. This model would be con-
sistent with current evidence that redefines LTBI as a
dynamic spectrum rather than a homogeneous state
[86]. Further research is needed to define the potential
role of LTBI in CVD, as this could have important impli-
cations worldwide.
Conclusions
With increasing evidence that many infections con-
tribute to the pathogenesis of CVD, the potential role
of tuberculosis in CVD is not surprising. A potential
mechanistic model for this association is based on re-
search showing persistent immune activation in latent
and active tuberculosis. Antibodies to mycobacterial
HSP65 cross-reacting with self-antigens in human
vessels leading to autoimmunity may also have an ef-
fect on CVD risk. Further research to investigate the
potential link between tuberculosis and CVD is
warranted.
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